ImmunityBio director Simon sells 25,000 shares

The reported sale prices ranged from $10.665 to $10.78 per share.

Rhea-AI Filing Summary

ImmunityBio, Inc. (IBRX) director Barry J. Simon reported selling 25,000 shares on October 5, 2026, at a weighted average price of $10.7504 per share. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted December 18, 2025. After the sale, Simon reported directly holding 2,777,788 shares.

Insider Trade Summary 10b5-1

Net Seller: 25,000 shares

Net Sell 1 txn

Insider Simon Barry J.

Role Director

Sold 25,000 shs ($269K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	25,000	$10.7504	$269K

Holdings After Transaction: Common Stock — 2,777,788 shares (Direct)

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.
2. F2. Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $10.665 to $10.78 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 25,000 shares Weighted average sale price: $10.7504 per share Reported sale price range: $10.665 to $10.78 per share +1 more

4 metrics

Shares sold 25,000 shares October 5, 2026

Weighted average sale price $10.7504 per share Sale on October 5, 2026

Reported sale price range $10.665 to $10.78 per share Prices for the 25,000 shares sold

Shares held directly after sale 2,777,788 shares Following the October 5, 2026 sale

Key Terms

Rule 10b5-1 trading plan, weighted average share price, price range

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average share price financial

"weighted average share price of an aggregate total"

price range financial

"shares sold in the price range of $10.665 to $10.78"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IBRX shares did Barry J. Simon sell, and at what price?

Barry J. Simon sold 25,000 shares on October 5, 2026, at a weighted average price of $10.7504 per share. The reported sale prices ranged from $10.665 to $10.78 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 06:06 PM Accepted by SEC EDGAR 10/06/2026 - 06:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Barry J.

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/05/2026		S(1)		25,000	D	$10.7504(2)	2,777,788	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025.

2. Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $10.665 to $10.78 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Remarks:

	/s/ Philip LoScalzo, as Attorney-in-Fact	10/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)